GXGanfeng Xie

Ganfeng Xie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ganfeng Xie has a total of 110 co-authors. Here are the top co-authors by number of shared publications:

  • Houjie Liang

    Department of Oncology and Southwest Cancer Centre, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, People’s Republic Of China

    7 shared publications
  • Juanjuan Ou

    Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China

    6 shared publications
  • Shuang Wu

    Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, P.R. China

    6 shared publications
  • Lisha Xiang

    Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China

    5 shared publications
  • Chengxiang Liu

    Department of Oncology and Southwest Cancer Centre, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China

    3 shared publications
  • Chi Zhang

    Department of Oncology and Southwest Cancer Centre, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China

    3 shared publications

Latest Publications

  • Open Access

    Prolyl hydroxylase 2 inhibits glycolytic activity in colorectal cancer via the NF‑κB signaling pathway

    by Lisha Xiang, Hao Wei, Wentao Ye, Shuang Wu, Ganfeng Xie

    A variety of malignancies preferentially meet energy demands through the glycolytic pathway. Hypoxia‑induced cancer cell adaptations are essential for tumor development. However, in cancerous glycolysis, the functional importance and underlying molecular mechanism of prolyl hydroxylase domain protein 2 (PHD2) have not been fully elucidated. Gain‑ and loss‑of‑function assays were conducted to evaluate PHD2 functions in colon cancer cells. Glucose uptake, lactate production and intracellular adenosine‑5'‑triphosphate/adenosine diphosphate ratio were measured to determine glycolytic activities. Protein and gene expression levels were measured by western blot analysis and reverse transcription‑quantitative PCR, respectively. The human colon cancer xenograft model was used to confirm the role of PHD2 in tumor progression in vivo. Functionally, the data demonstrated that PHD2 knockdown leads to increased glycolysis, while PHD2 overexpression resulted in suppressed glycolysis in colorectal cancer cells. In addition, the glycolytic activity was enhanced without PHD2 and normalized after PHD2 reconstitution. PHD2 was shown to inhibit colorectal tumor growth, suppress cancer cell proliferation and improve tumor‑bearing mice survival in vivo. Mechanically, it was found that PHD2 inhibits the expression of critical glycolytic enzymes (glucose transporter 1, hexokinase 2 and phosphoinositide‑dependent protein kinase 1). In addition, PHD2 inhibited Ikkβ‑mediated NF‑κB activation in a hypoxia‑inducible factor‑1α‑independent manner. In conclusion, the data demonstrated that PHD2/Ikkβ/NF‑κB signaling has critical roles in regulating glycolysis and suggests that PHD2 potentially suppresses colorectal cancer.


  • Open Access

    Pure Organic AIE Nanoscintillator for X‐ray Mediated Type I and Type II Photodynamic Therapy (Adv. Sci. 26/2023)

    by Yuewen Yu, Lisha Xiang, Xuanwei Zhang, Le Zhang, Zhiqiang Ni, Zhong‐Hong Zhu, Yubo Liu, Jie Lan, Wei Liu, Ganfeng Xie, et al.


  • HILPDA-mediated lipidomic remodelling promotes radiotherapy resistance in nasopharyngeal carcinoma by accelerating mitophagy

    by Yue Zhang, Chen Pang, Chi Zhang, Yijie Wang, Peng Wang, Yanrong Chen, Junyi Wang, Ying Hu, Chengxiang Liu, Houjie Liang, et al.

    Radiotherapy resistance is a major obstacle to nasopharyngeal carcinoma (NPC) therapy and contributes to tumour recurrence and metastasis. Lipid metabolism is a key regulatory mechanism in cancer biology; however, its role in NPC radiotherapy resistance remains unclear. In this study, we identified hypoxia-inducible lipid droplet-associated protein (HILPDA) as a newly discovered regulator of radioresistance that induces not only lipid droplet (LD) formation but also intracellular lipid remodelling, notably changing mitochondrial cardiolipin (CL) levels. Additionally, we found that the upregulation of CL promotes mitophagy in response to irradiation exposure. Mechanistically, HILPDA inhibits PINK1-mediated CLS1 ubiquitination and degradation. The combination of a mitophagy inhibitor and irradiation significantly increases the radiosensitivity of NPC cells. Human cancer-derived data confirmed that the HILPDA-CLS1 pathway promotes NPC radioresistance. Collectively, these findings suggest that HILPDA plays a critical role in promoting NPC radioresistance and might be targeted to overcome radiotherapeutic resistance in NPC patients in the clinic.


  • Open Access

    Pure Organic AIE Nanoscintillator for X‐ray Mediated Type I and Type II Photodynamic Therapy

    by Yuewen Yu, Lisha Xiang, Xuanwei Zhang, Le Zhang, Zhiqiang Ni, Zhong‐Hong Zhu, Yubo Liu, Jie Lan, Wei Liu, Ganfeng Xie, et al.

    X‐ray induced photodynamic therapy (X‐PDT) circumvents the poor penetration depth of conventional PDT with minimal radio‐resistance generation. However, conventional X‐PDT typically requires inorganic scintillators as energy transducers to excite neighboring photosensitizers (PSs) to generate reactive oxygen species (ROS). Herein, a pure organic aggregation‐induced emission (AIE) nanoscintillator (TBDCR NPs) that can massively generate both type I and type II ROS under direct X‐ray irradiation is reported for hypoxia‐tolerant X‐PDT. Heteroatoms are introduced to enhance X‐ray harvesting and ROS generation ability, and AIE‐active TBDCR exhibits aggregation‐enhanced ROS especially less oxygen‐dependent hydroxyl radical (HO•−, type I) generation ability. TBDCR NPs with a distinctive PEG crystalline shell to provide a rigid intraparticle microenvironment show further enhanced ROS generation. Intriguingly, TBDCR NPs show bright near‐infrared fluorescence and massive singlet oxygen and HO•− generation under direct X‐ray irradiation, which demonstrate excellent antitumor X‐PDT performance both in vitro and in vivo. To the best of knowledge, this is the first pure organic PS capable of generating both 1O2 and radicals (HO•−) in response to direct X‐ray irradiation, which shall provide new insights for designing organic scintillators with excellent X‐ray harvesting and predominant free radical generation for efficient X‐PDT.


  • Open Access

    Author Correction: ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation

    by Yan Gu, Yanrong Chen, Lai Wei, Shuang Wu, Kaicheng Shen, Chengxiang Liu, Yan Dong, Yang Zhao, Yue Zhang, Chi Zhang, et al.

  • HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression

    by Lisha Xiang, Yongsheng Wang, Jie Lan, Feifei Na, Shuang Wu, Yuzhu Gong, Hanjian Du, Bin Shao, Ganfeng Xie

    Gemcitabine is commonly used to treat various cancer types, including human non-small cell lung cancer (NSCLC). However, even cases that initially respond rapidly commonly develop acquired resistance, limiting our ability to effectively treat advanced NSCLC. To gain insight for developing a strategy to overcome gemcitabine resistance, the present study investigated the mechanism of gemcitabine resistance in NSCLC according to the involvement of ATP-binding cassette subfamily B member 6 (ABCB6) and heme biosynthesis. First, an analysis of ABCB6 expression in human NSCLCs was found to be associated with poor prognosis and gemcitabine resistance in a hypoxia-inducible factor (HIF)-1-dependent manner. Further experiments showed that activation of HIF-1α/ABCB6 signaling led to intracellular heme metabolic reprogramming and a corresponding increase in heme biosynthesis to enhance the activation and accumulation of catalase. Increased catalase levels diminished the effective levels of reactive oxygen species, thereby promoting gemcitabine-based resistance. In a mouse NSCLC model, inhibition of HIF-1α or ABCB6, in combination with gemcitabine, strongly restrained tumor proliferation, increased tumor cell apoptosis, and prolonged animal survival. These results suggest that, in combination with gemcitabine-based chemotherapy, targeting HIF-1α/ABCB6 signaling could result in enhanced tumor chemosensitivity and, thus, may improve outcomes in NSCLC patients.


  • Top Cited Papers

    Cationization to boost both type I and type II ROS generation for photodynamic therapy

    by Yuewen Yu, Shuang Wu, Le Zhang, Shidang Xu, Chunhui Dai, Shengming Gan, Ganfeng Xie, Guangxue Feng, Ben Zhong Tang


  • Open Access

    ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation

    by Yan Gu, Yanrong Chen, Lai Wei, Shuang Wu, Kaicheng Shen, Chengxiang Liu, Yan Dong, Yang Zhao, Yue Zhang, Chi Zhang, et al.

    Cancer stemness represents a major source of development and progression of colorectal cancer (CRC). c-Met critically contributes to CRC stemness, but how c-Met is activated in CRC remains elusive. We previously identified the lipolytic factor ABHD5 as an important tumour suppressor gene in CRC. Here, we show that loss of ABHD5 promotes c-Met activation to sustain CRC stemness in a non-canonical manner. Mechanistically, we demonstrate that ABHD5 interacts in the cytoplasm with the core subunit of the SET1A methyltransferase complex, DPY30, thereby inhibiting the nuclear translocation of DPY30 and activity of SET1A. In the absence of ABHD5, DPY30 translocates to the nucleus and supports SET1A-mediated methylation of YAP and histone H3, which sequesters YAP in the nucleus and increases chromatin accessibility to synergistically promote YAP-induced transcription of c-Met, thus promoting the stemness of CRC cells. This study reveals a novel role of ABHD5 in regulating histone/non-histone methylation and CRC stemness.


  • Open Access

    HIF-1-Dependent Heme Synthesis Promotes Gemcitabine Resistance In Human Non-Small Cell Lung Cancers Via Enhanced ABCB6 Expression

    by Lisha Xiang, Xiaoyu Li, Yongsheng Wang, Jie Lan, Feifei Na, Shuang Wu, Yuzhu Gong, Bin Shao, Ganfeng Xie

    Background: Gemcitabine, a deoxycytidine analogue, is commonly used in the treatment of various types of tumors, including human non-small cell lung cancer (NSCLC). However, even the initial responders rapidly develop acquired resistance which limits our ability to effectively treat advanced NSCLC. The present study reports a widely prevalent mechanism of resistance to gemcitabine in NSCLC, whereby induced expression of ABCB6 is associated with poor prognosis and gemcitabine resistance in human NSCLCs which is in a HIF-1-dependent manner.Methods: We established gemcitabine resistant LUSC and LUAD cells and examined ABCB6 expression as well as heme synthesis in these cells. Additionally, we analyzed catalase protein expression and activity in gemcitabine resistant NSCLC cell lines. To validate ABCB6 gene as an HRE, we performed ChIP-qPCR assay. We also investigated the effect of inhibition of HIF-α/ABCB6 axis in vitro and in vivo.Results: The activation of HIF-1α/ABCB6 signaling leading to intracellular heme metabolic reprogramming and a corresponding increase in heme biosynthesis to enhance the activation and accumulation of catalase. Increased levels of catalase diminish the effective levels of reactive oxygen species (ROS) promoting gemcitabine-based resistance. Targeting HIF-1α or ABCB6, in combination with gemcitabine, strongly restrains tumor proliferation, increases tumor cell apoptosis and prolongs animal survival.Conclusion: In combination with gemcitabine-based chemotherapy, targeting HIF-1α/ABCB6 signaling could result in enhanced tumor sensitivity to chemotherapeutic agent and may improve outcome in NSCLCs.

  • Open Access

    Vascular NRP2 triggers PNET angiogenesis by activating the SSH1-cofilin axis

    by Xi Luo, Jiang-Yi He, Jie Xu, Shao-Yi Hu, Bang-Hui Mo, Qiu-Xia Shu, Can Chen, Yu-Zhu Gong, Xiao-Long Zhao, Gan-Feng Xie, et al.

    Background: Angiogenesis is a critical step in the growth of pancreatic neuroendocrine tumors (PNETs) and may be a selective target for PNET therapy. However, PNETs are robustly resistant to current anti-angiogenic therapies that primarily target the VEGFR pathway. Thus, the mechanism of PNET angiogenesis urgently needs to be clarified. Methods: Dataset analysis was used to identify angiogenesis-related genes in PNETs. Immunohistochemistry was performed to determine the relationship among Neuropilin 2 (NRP2), VEGFR2 and CD31. Cell proliferation, wound-healing and tube formation assays were performed to clarify the function of NRP2 in angiogenesis. The mechanism involved in NRP2-induced angiogenesis was detected by constructing plasmids with mutant variants and performing Western blot, and immunofluorescence assays. A mouse model was used to evaluate the effect of the NRP2 antibody in vivo, and clinical data were collected from patient records to verify the association between NRP2 and patient prognosis. Results: NRP2, a VEGFR2 co-receptor, was positively correlated with vascularity but not with VEGFR2 in PNET tissues. NRP2 promoted the migration of human umbilical vein endothelial cells (HUVECs) cultured in the presence of conditioned medium PNET cells via a VEGF/VEGFR2-independent pathway. Moreover, NRP2 induced F-actin polymerization by activating the actin-binding protein cofilin. Cofilin phosphatase slingshot-1 (SSH1) was highly expressed in NRP2-activating cofilin, and silencing SSH1 ameliorated NRP2-activated HUVEC migration and F-actin polymerization. Furthermore, blocking NRP2 in vivo suppressed PNET angiogenesis and tumor growth. Finally, elevated NRP2 expression was associated with poor prognosis in PNET patients. Conclusion: Vascular NRP2 promotes PNET angiogenesis by activating the SSH1/cofilin/actin axis. Our findings demonstrate that NRP2 is an important regulator of angiogenesis and a potential therapeutic target of anti-angiogenesis therapy for PNET.